PMID- 1325076
OWN - NLM
STAT- MEDLINE
DCOM- 19920929
LR  - 20061115
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 68
IP  - 1
DP  - 1992 Jul 6
TI  - Subcutaneous low molecular weight heparin versus subcutaneous unfractionated 
      heparin in the treatment of deep vein thrombosis: a Polish multicenter trial.
PG  - 14-8
AB  - In a prospective multicenter trial, 149 consecutive patients with 
      phlebographically proven proximal and/or distal deep vein thrombosis of the leg 
      were randomly allocated to receive subcutaneously for 10 days either low 
      molecular weight heparin CY 216 (Fraxiparine) in a fixed dose or unfractionated 
      heparin (UFH) in doses adjusted according to the activated partial thromboplastin 
      time. Pre- and post-treatment phlebograms were assessed blindly using the 
      Arnesen's score system in 134 patients available for analysis of the treatment 
      efficacy. The mean phlebographic score after 10 days of treatment was 
      significantly decreased in both groups (p less than 0.001) in comparison with the 
      baseline score but the difference in score changes between the two groups was not 
      statistically significant. There was an improvement in 45/68 patients (66%) in 
      the Fraxiparine group and in 32/66 patients (48%) in the UFH group, and an 
      increase in the thrombus size in 10/68 (15%) and 12/66 (18%), respectively. One 
      symptomatic non-fatal pulmonary embolism and one major bleeding episode were 
      observed in the UFH group. During a follow-up period of 3 months, two 
      rethromboses had occurred in the UFH group and none in the Fraxiparine group. It 
      is concluded that subcutaneous fixed dose Fraxiparine is safe and at least as 
      effective as subcutaneous adjusted UFH in the treatment of deep vein thrombosis.
FAU - Lopaciuk, S
AU  - Lopaciuk S
AD  - Institute of Hematology, Warsaw, Poland.
FAU - Meissner, A J
AU  - Meissner AJ
FAU - Filipecki, S
AU  - Filipecki S
FAU - Zawilska, K
AU  - Zawilska K
FAU - Sowier, J
AU  - Sowier J
FAU - Ciesielski, L
AU  - Ciesielski L
FAU - Bielawiec, M
AU  - Bielawiec M
FAU - Glowinski, S
AU  - Glowinski S
FAU - Czestochowska, E
AU  - Czestochowska E
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Adult
MH  - Double-Blind Method
MH  - Female
MH  - Heparin/*administration & dosage/adverse effects
MH  - Heparin, Low-Molecular-Weight/*administration & dosage/adverse effects
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Male
MH  - Middle Aged
MH  - Phlebography
MH  - Poland
MH  - Prospective Studies
MH  - Thrombophlebitis/*drug therapy
EDAT- 1992/07/06 00:00
MHDA- 1992/07/06 00:01
CRDT- 1992/07/06 00:00
PHST- 1992/07/06 00:00 [pubmed]
PHST- 1992/07/06 00:01 [medline]
PHST- 1992/07/06 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1992 Jul 6;68(1):14-8.